Latest stories on DYN
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
Stocktwits News38 · neutralgeneral
Dyne extends slide as J.P. Morgan downgrades on Novartis setback
Seeking Alpha34 · bearishanalyst
Dyne Therapeutics stock price target lowered to $30 by RBC Capital
Investing.com Analyst Ratings34 · bearishanalyst
Dyne Therapeutics price target lowered to $36 from $45 at Morgan Stanley
The Fly34 · bearishanalyst
Dyne Therapeutics price target lowered to $30 from $35 at RBC Capital
The Fly34 · bearishanalyst
Dyne Therapeutics Remains A Buy Even As Novartis Trial Failure Hits DM1 Class
Seeking Alpha58 · neutralanalyst
Dyne Therapeutics price target lowered to $26 from $30 at Baird
The Fly38 · neutralanalyst
Dyne Therapeutics downgraded to Underweight from Neutral at JPMorgan
The Fly38 · neutralanalyst
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
Stocktwits News22 · bearishearnings
Dyne Therapeutics falls -15.4%
The Fly35 · bearishearnings
Raymond James cuts Dyne Therapeutics price target on DM1 trial risk
Investing.com Analyst Ratings34 · bearishanalyst
Dyne Therapeutics falls -22.3%
The Fly30 · bearishearnings
Dyne Therapeutics should be bought on weakness, says Stifel
The Fly63 · neutralanalyst
Dyne Therapeutics sinks after Novartis myotonic dystrophy miss
The Fly32 · bearishearnings
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
Yahoo Top34 · bearishgeneral
Dyne Therapeutics Shares Fall 31% Premarket With No Catalyst Confirmed
InvestorsHub34 · bearishgeneral
Dyne Therapeutics stock faces pressure after rival drug fails trial
Investing.com Analyst Ratings38 · neutralgeneral
Why is Dyne Therapeutics stock plummeting today?
Investing.com Markets32 · bearishgeneral
Dyne Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Business Insider56 · neutralgeneral
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Insider50 · neutralgeneral
Wainwright reiterates Dyne Therapeutics stock rating on trial outlook
Investing.com Analyst Ratings56 · neutralanalyst